Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. Paridaens R, et al. Among authors: klijn jg. J Clin Oncol. 2000 Feb;18(4):724-33. doi: 10.1200/JCO.2000.18.4.724. J Clin Oncol. 2000. PMID: 10673513 Clinical Trial.
Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: a double-blind randomized study. European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Paridaens R, Heuson JC, Julien JP, Veyret C, Van Zyl J, Klijn JG, Sylvester R, Mignolet F. Paridaens R, et al. Among authors: klijn jg. J Clin Oncol. 1993 Sep;11(9):1723-8. doi: 10.1200/JCO.1993.11.9.1723. J Clin Oncol. 1993. PMID: 8355039 Clinical Trial.
Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
Bontenbal M, Andersson M, Wildiers J, Cocconi G, Jassem J, Paridaens R, Rotmensz N, Sylvester R, Mouridsen HT, Klijn JG, van Oosterom AT. Bontenbal M, et al. Among authors: klijn jg. Br J Cancer. 1998 Jun;77(12):2257-63. doi: 10.1038/bjc.1998.375. Br J Cancer. 1998. PMID: 9649142 Free PMC article. Clinical Trial.
Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist.
Kramer JA, Curran D, Piccart M, de Haes JC, Bruning PF, Klijn JG, Bontenbal M, van Pottelsberghe C, Groenvold M, Paridaens R. Kramer JA, et al. Among authors: klijn jg. Eur J Cancer. 2000 Aug;36(12):1488-97. doi: 10.1016/s0959-8049(00)00134-9. Eur J Cancer. 2000. PMID: 10930796 Clinical Trial.
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Klijn JG, et al. J Clin Oncol. 2001 Jan 15;19(2):343-53. doi: 10.1200/JCO.2001.19.2.343. J Clin Oncol. 2001. PMID: 11208825
Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: preliminary results of a double-blind randomized study of the EORTC Breast Cancer Cooperative Group.
Paridaens R, Heuson JC, Julien JP, Veyret C, van Zijl J, Klijn JG, Sylvester RJ, Mignolet F. Paridaens R, et al. Among authors: klijn jg. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1109-13. doi: 10.1016/0960-0760(90)90474-y. J Steroid Biochem Mol Biol. 1990. PMID: 2285584 Clinical Trial.
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group).
Bruning PF, Bonfrer JM, Paridaens R, Nooij M, Klijn JG, Beex LV, Bruynseels J, Piccart MJ. Bruning PF, et al. Among authors: klijn jg. Anticancer Drugs. 1998 Jun;9(5):419-25. doi: 10.1097/00001813-199806000-00008. Anticancer Drugs. 1998. PMID: 9660539 Clinical Trial.
Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
Klijn JG, de Voogt HJ, Studer UE, Schröder FH, Sylvester R, De Pauw M. Klijn JG, et al. Cancer. 1993 Dec 15;72(12 Suppl):3858-62. doi: 10.1002/1097-0142(19931215)72:12+<3858::aid-cncr2820721719>3.0.co;2-6. Cancer. 1993. PMID: 8252504 Clinical Trial.
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.
de Voogt HJ, Studer U, Schröder FH, Klijn JG, de Pauw M, Sylvester R. de Voogt HJ, et al. Among authors: klijn jg. Eur Urol. 1998;33(2):152-8. doi: 10.1159/000019547. Eur Urol. 1998. PMID: 9519356 Clinical Trial.
343 results